Altered expression of costimulatory molecules in myasthenia gravis

Muscle and Nerve

Volumn 23, Issue 6, 2000, Pages 946-953

  Teleshova, Natalia ^a   Matusevicius, Darius ^a   Kivisäkk, Pia ^a   Mustafa, Maha ^a   Pirskanen, Ritva ^a   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD28 CD80 CD86; CD40 CD40L; Costimulatory molecules; Myasthenia gravis

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN GP 39;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MALE; MYASTHENIA GRAVIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; AUTOANTIBODIES; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CD40 LIGAND; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 0034083233     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200006)23:6<946::AID-MUS16>3.0.CO;2-4     Document Type: Article

References (44)

1. Aarli JA. Late-onset myasthenia gravis: a changing scene. Arch Neurol 1999;56:25-27.
2. Berrih S, Gaud C, Bach MA, Le Brigand H, Binet JP, Bach JF. Evaluation of T cell subsets of myasthenia gravis using anti-T-cell monoclonal antibodies. Clin Exp Immunol 1981;45:1-8.
3. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555-559.
4. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2: CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 1996;153: 5-26.
5. Christiansen FT, Pollack MS, Garlepp PMJ, Dawkins RL. Myasthenia gravis and HLA antigens in American blacks and other races. J Neuroimmunol 1984;7:121-129.
6. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in mysthenia gravis. Brain 1980;103:579-601.
7. De Boer M, Kasran A, Kwekkeboom J, Walter H, Vandenberghe P, Ceuppenns JL. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 1993;23:3120-3125.
8. De Franco AL. Molecular aspects of B-lymphocyte activation. Annu Rev Cell Biol 1987;3:143-178.
9. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40:786-790.
10. Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G, Franceschi C, Passeri M, Sansoni P. Expansion of cytotoxic CD8+CD28- T cells in healthy ageing people, including centenarians. Immunology 1996;88:501-507.
11. Fujii N, Itoyama Y, Tabira T, Kuroiwa Y. Subsets of lymphoid cells in blood and thymus in myasthenia gravis. Monoclonal antibody analysis. J Neuroimmunol 1983;4:151-159.
12. Grosse-Wilde H, Toyka KV, Besinger UA, Doxiadis I, Heininget K, Homberg M, Homberg V, Hohfeld R, Fateh-Moghadam A, Jungwirth J, Kreeb G, Vogeler U. Immunogenetics of myasthenia gravis. Significance of HLA-, complement and Cm gene systems for clinical and immunologic parameters. Dtsch Med Wochenschr 1983;108:694-700.
13. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356:607-609.
14. Klaus SJ, Pinchuk LM, Ochs HD, Law CL, Fanslow WC, Armitage RJ, Clark EA. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. J Immunol 1994;152:5643-5652.
15. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-837.
16. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-718.
17. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995;154:97-105.
18. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990;8:773-793.
19. Lefvert AK, Bergström K. Acetylcholine receptor antibody in myasthenia gravis: purification and characterization. Scand J Immunol 1978;8:525-533.
20. Lennon VA, Lindström JM, Seybold ME. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann NY Acad Sci 1976;274:283-299.
21. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996;5:285-293.
22. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-1155.
23. Limburg PC, The TH, Hummel-Tappel K, Oosteruis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part I: relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357-370.
24. Link H, Olsson O, Sun J, Wang W-Z, Andersson G, Ekre H-P, Brenner T, Abramsky O, Olsson T. Acethylcholine receptor reactive T and B cells in myasihenia gravis and controls. J Clin Invest 1991;87:2191-2195.
25. Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter JA. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 and prolonged unresponsiveness to CD28 signaling. J Immunol 1993;150:3161-3169.
26. Lisak RP, Laramore C, Levinson AI, Zweiman B, Moskovitz AR, Witte A. In vitro synthesis of antibodies to acethylcholine receptor by peripheral blood cells: role of supressor T cells in normal subjects. Neurology 1984;34:802-805.
27. Lisak RP, Zweiman B, Philips SM. Thymic and peripheral blood T- and B-cell levels in myasthenia gravis. Neurology 1978;28:1298-1301.
28. Lopate G, Pestronk A. The myasthenic neuromuscular junction. In: Lisak RP editor: Handbook of myasthenia gravis and myasthenic syndromes. Vol. 23. New York: Marcel Dekker; 1984. p 225-237.
29. Marx A, Schomig D, Schultz A, Gattenlohner S, Jung A, Kirchner T, Melms A, Muller-Hermelink HK. Distribution of molecules mediating thymocyte-stroma-interactions in human thymus, thymitis and thymic epithelial tumors. Thymus 1994; 23:83-93.
30. Moosig F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol 1998; 114:113-118.
31. Newsom-Davis J, Willcox N, Calder L. Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody in autologous blood lymphocytes. N Engl J Med 1981;305:1313-1318.
32. Oosterhuis HJGH. Studies in myasthenia gravis. Part 1. A clinical study of 180 patients. J Neurol Sci 1964;1:512-546.
33. Park W, Weyand CM, Schmidt D, Goronzy JJ. Costimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells. Eur J Immunol 1997;27: 1082-1097.
34. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993;11:331-360.
35. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ. Distinct roles for B7-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96:2195-2203.
36. Ragheb S, Lisak RP. Effect of clinical status and treatment on the frequency of CD5+ B-cells in patients with myasthenia gravis. Neurology 1992;42:1076-1080.
37. Ragheb S, Lisak RP. Phenotypic and functional abnormalities of B-cells in myasthenia gravis. Ann NY Acad Sci 1993;681: 256-263.
38. Ragheb S, Lisak RP. The immunopathogenesis of acquired (autoimmune) myasthenia gravis. In: Lisak RP, editor: Handbook of myasthenia gravis and myasthenic syndromes, Vol. 23. New York: Marcel Dekker; 1984. p 239-276.
39. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4- T cells. J Immunol 1993;151: 2947-2510.
40. Skolnik PR, Lisak RP, Zweiman B. Monoclonal antibody analysis of blood T cell subsets in myasthenia gravis. Ann Neurol 1982;11:170-176.
41. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996;17:487-492.
42. Wheatley LM, Urso D, Zheng Y, Loh E, Levinson AI. Molecular analysis of intrathymic nicotinic acethylcholine receptor. Ann NY Acad Sci 1993;681:74-82.
43. Zhang GX, Navikas V, Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 1997;20:543-551.
44. Zhang GX, Yu LY, Shi FD, Xiao BG, Bjork J, Hedlung G, Link H. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. J Neuroimmunol 1997;73:175-182.